Baidu
map

Prostate:在前列腺癌中,MCM10的过表达能够促进细胞的增殖和预测不良预后

2018-08-15 AlexYang MedSci原创

前列腺癌(PCa)是男性泌尿生殖系统中最常见的恶性肿瘤之一。鉴定新的PCa生物标记十分紧迫和必要。最近,有研究人员通过分析公共数据库评估了MCM10在前列腺癌中的表达水平。进一步的是,研究人员进行了功能缺失试验分析来评估MCM10对细胞增殖、细胞凋亡和克隆形成的影响。更多的是,研究人员还利用基因芯片和生物信息学分析探索了MCM10潜在的作用机制。研究发现,他们首次阐释了MCM10在PCa中表达是显

前列腺癌(PCa)是男性泌尿生殖系统中最常见的恶性肿瘤之一。鉴定新的PCa生物标记十分紧迫和必要。最近,有研究人员通过分析公共数据库评估了MCM10在前列腺癌中的表达水平。进一步的是,研究人员进行了功能缺失试验分析来评估MCM10对细胞增殖、细胞凋亡和克隆形成的影响。更多的是,研究人员还利用基因芯片和生物信息学分析探索了MCM10潜在的作用机制。

研究发现,他们首次阐释了MCM10在PCa中表达是显著上调的。他们还发现,MCM10表达的上调与晚期临床阶段和高格林森PCa评分显著相关。Kaplan-Meier分析阐释了更高的MCM10表达与PCa患者不良的预后相关。进一步的是,功能缺失试验表明了MCM10的敲除能够抑制细胞增殖和克隆形成,但是能够促进细胞凋亡。另外,研究人员的基因芯片和生物信息学分析表明MCM10能够通过调节一系列的生物过程,包括癌症、细胞死亡和凋亡,来调控PCa进展。

最后,研究人员指出,他们的研究结果表明了MCM,10可能是PCa潜在的诊断和治疗靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2019-06-17 lq1767
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-09-06 jyzxjiangqin

    前列腺增生微创治疗。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-28 jyzxjiangqin

    前列腺癌靶向药物治疗。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-17 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958181, encodeId=2ba3195818168, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Mon Jun 17 08:39:00 CST 2019, time=2019-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343269, encodeId=34623432698e, content=前列腺增生微创治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Sep 06 15:54:14 CST 2018, time=2018-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341503, encodeId=96c834150390, content=前列腺癌靶向药物治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Tue Aug 28 20:42:41 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336370, encodeId=1ccc13363e035, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364370, encodeId=8e2513643e00e, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602044, encodeId=8f5816020449b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Aug 17 02:39:00 CST 2018, time=2018-08-17, status=1, ipAttribution=)]
    2018-08-17 sunylz

相关资讯

Sci Rep:在前列腺癌中,骨形态生成蛋白-2表达的减少与生化复发相关

最近,有研究人员在前列腺癌患者中利用免疫组化技术在前列腺癌组织中评估了BMP-2的表达的预后价值情况。研究人员在2007年7月到2010年8月之间,在患有局部前列腺癌(平均年龄,62.7岁;平均跟踪调查时间90.4个月)的90名患者的根治性前列腺切除样本中利用免疫组化技术评估了BMP-2的表达情况,并利用逐步多变量Cox回归模型分层方法评估了预测因素和评估的风险比(HRs)的独立效应。研究发现,在

Oncogene:在CRPC中,KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢

在进化到去雄抗性或者治疗抗性的历程中,前列腺癌细胞重新调整了雄性激素的响应来应对雄性激素水平的降低,并且针对营养的匮乏和缺氧条件进行代谢适应。AR(雄性激素受体)和PKM2(丙酮酸激酶M2)在这些过程中具有关键的作用。最近,有研究人员报道了KDM8/JMJD5,一个组蛋白赖氨酸脱甲基酶/脱氧酶,展现出了作为AR和PKM2的双激活剂特性,因此它也是去雄抗性和治疗抗性的潜在诱导因子。之前,研究人员展现

JAMA Oncol:局限性前列腺癌患者,吸烟对切除术或放疗后的结局有何影响?

2018年7月,发表在《JAMA Oncol》的一项由澳大利亚、瑞士、西班牙、约旦等国学者进行的系统评价和Meta分析,考察了吸烟状态与行前列腺切除术或放疗的局限性前列腺癌患者复发、转移和死亡的相关性。

Cell:全面解锁不可用药的前列腺癌靶点

《Cell》报道,阻断核孔控制促癌分子流量即可限制侵袭性癌症发展。

Communications Biology:嵌合体ARCC-4靶向蛋白酶水解作用引起的雄激素受体降解要比恩杂鲁胺效果更好

雄激素受体是前列腺癌的一种主要驱使因子,利用竞争性拮抗剂对其转录活性的抑制,比如恩杂鲁胺,仍旧是前列腺癌治疗的一线疗法。然而,大多数的患者最终均发展出药物抗性。最近,有研究人员认为通过蛋白酶水解靶向嵌合体(PROTACs)来以雄激素受体为靶标使其降解,将会成为前列腺癌细胞中靶向雄激素受体信号疗法的一种更好的治疗性策略。研究人员在由一个当前批准的雄激素受体拮抗剂恩杂鲁胺和它的PROTAC衍生物ARC

Molecular Cell:全新发现,这款药物不仅可治疗卵巢癌、前列腺癌及胰腺癌还可治疗脑部疾病!

肌萎缩侧索硬化ALS是运动神经元疾病,病程晚期进展为全身肌肉萎缩和吞咽困难,最后产生呼吸衰竭,TDP-43是一个重要的致病相关蛋白,宾夕法尼亚研究小组发现PARP抑制剂可以阻止 PAR的产生,从而减少TDP-43的有害影响,此项研究发表在《Molecular Cell》上。

Baidu
map
Baidu
map
Baidu
map